Literature DB >> 31189032

Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.

Stefanie Lerche1,2, Gerrit Machetanz1,2, Isabel Wurster1,2, Benjamin Roeben1,2, Milan Zimmermann1,2, Andrea Pilotto3,4, Oliver Preische2,5, Elke Stransky1, Christian Deuschle1,2, Ann-Kathrin Hauser1,2, Claudia Schulte1,2, Ingolf Lachmann6, Katharina Waniek6, Thomas Gasser1,2, Daniela Berg7, Walter Maetzler7, Kathrin Brockmann1,2.   

Abstract

BACKGROUND: Patients with dementia with Lewy bodies reveal a variable pathology including alpha-synuclein, amyloid-beta, and Tau. Mutations in GBA1 are specifically associated with synucleinopathies. PD patients with GBA1 mutations show reduced CSF levels of total alpha-synuclein.
OBJECTIVE: Whether GBA1 mutations are associated with a CSF alpha-synuclein profile in dementia with Lewy bodies.
METHODS: Screening of the GBA1 gene and single-nucleotide polymorphisms in SNCA rs356220, APOE rs429358, and MAPT rs1052587 as well as CSF levels of total alpha-synuclein, amyloid-beta1-42 , total-Tau, phospho-Tau, and neurofilament light chain were assessed in 100 dementia with Lewy bodies and 39 controls cross-sectionally.
RESULTS: Severity of GBA1 mutations was associated with a younger age at onset and higher prevalence of rapid eye movement sleep behavior disorder. CSF levels of total alpha-synuclein were lowest in DLBGBA_pathogenic compared to DLBGBA_mild and DLBGBA_wildtype .
CONCLUSION: Similar to PD, pathogenic GBA1 mutations seem to be associated with CSF alpha-synuclein profiles in dementia with Lewy bodies. That might be useful for patient stratification for specific alpha-synuclein-lowering compounds.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  CSF; DLB; GBA; alpha-synuclein

Mesh:

Substances:

Year:  2019        PMID: 31189032     DOI: 10.1002/mds.27731

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses.

Authors:  Li Liu; Jia Li; Wei Quan; Yidan Qin; Qinghui Zhang; Xiaochen Pei; Hang Su; Jing Xu; Jiajun Chen
Journal:  Neurol Sci       Date:  2022-03-24       Impact factor: 3.307

2.  A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.

Authors:  Jonas M den Heijer; Valerie C Cullen; Marialuisa Quadri; Arnoud Schmitz; Dana C Hilt; Peter Lansbury; Henk W Berendse; Wilma D J van de Berg; Rob M A de Bie; Jeffrey M Boertien; Agnita J W Boon; M Fiorella Contarino; Jacobus J van Hilten; Jorrit I Hoff; Tom van Mierlo; Alex G Munts; Anne A van der Plas; Mirthe M Ponsen; Frank Baas; Danielle Majoor-Krakauer; Vincenzo Bonifati; Teus van Laar; Geert J Groeneveld
Journal:  Mov Disord       Date:  2020-07-02       Impact factor: 10.338

Review 3.  GBA-associated PD: chances and obstacles for targeted treatment strategies.

Authors:  Günter Höglinger; Claudia Schulte; Wolfgang H Jost; Alexander Storch; Dirk Woitalla; Rejko Krüger; Björn Falkenburger; Kathrin Brockmann
Journal:  J Neural Transm (Vienna)       Date:  2022-05-31       Impact factor: 3.850

4.  Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding.

Authors:  Isabel Wurster; Corinne Quadalti; Marcello Rossi; Ann-Kathrin Hauser; Christian Deuschle; Claudia Schulte; Katharina Waniek; Ingolf Lachmann; Christian la Fougere; Kathrin Doppler; Thomas Gasser; Benjamin Bender; Piero Parchi; Kathrin Brockmann
Journal:  NPJ Parkinsons Dis       Date:  2022-09-15

Review 5.  Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

Authors:  Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

Review 6.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

Review 7.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

8.  Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.

Authors:  Olivier Bousiges; Nathalie Philippi; Thomas Lavaux; Armand Perret-Liaudet; Ingolf Lachmann; Caroline Schaeffer-Agalède; Pierre Anthony; Anne Botzung; Lucie Rauch; Barbara Jung; Paulo Loureiro de Sousa; Catherine Demuynck; Catherine Martin-Hunyadi; Benjamin Cretin; Frédéric Blanc
Journal:  Alzheimers Res Ther       Date:  2020-09-29       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.